A significant portion of institutional investors are positioning for potential market volatility in 2026, with 74% of money managers anticipating a market correction within the year. This defensive posture has renewed focus on dividend-paying healthcare companies that have demonstrated resilience during economic downturns.
AbbVie and Merck have emerged as particular points of interest for investors seeking stability and income. Both pharmaceutical leaders maintain dividend yields ranging from 2.7% to 3.1% and have sustained consecutive annual dividend increases exceeding 13 years, reflecting consistent earnings power and management confidence in long-term prospects. These companies have historically outperformed broader market indices during periods of heightened volatility, attributable to steady demand for pharmaceutical products regardless of economic conditions.
Analysts project both companies are positioned for solid growth in 2026, supported by their diversified product portfolios and established market positions. For investors concerned about near-term market turbulence, these established dividend payers offer a combination of current yield and capital appreciation potential, though performance outcomes remain dependent on broader market and economic conditions.